In particular in DS-ALL, RAS/MAPK-inhibition might be applicable to most HR patients, as we show that specifically samples stratified by our PCA as HR seemed resistant to treatment with PI3K/mTOR or JAK inhibitors alone while only RAS-inhibition slashed the viable cell count in half. Here, MTOR is linked to acute lymphoblastic leukemia.